News & Press

Do you have any questions about our news?

Do not hesitate to contact our press team:

press contacts
All news
Corporate
Brands
Sports
R&D

International Symposium: High Interest in Scientific Findings on Hydroxyapatite

Read more
03.04.2024

International Symposium: High Interest in Scientific Findings on Hydroxyapatite

At the General Session of the International Association for Dental Research (IADR), Dr. Wolff's research provided several important scientific insights for oral care, particularly regarding the effects of hydroxyapatite (HAP).

Read more

Dr. Wolff Presents Latest Research Findings on Hydroxyapatite Toothpaste at the World’s Most Significant Scientific Conference for Dental Research

Read more
16.02.2024

Dr. Wolff Presents Latest Research Findings on Hydroxyapatite Toothpaste at the World’s Most Significant Scientific Conference for Dental Research

At the IADR General Session & Exhibition 2024 in New Orleans, Dr. Wolff will present several scientific contributions focusing on hydroxyapatite as active ingredient in oral care.

Read more

Successfully combating chalky teeth, grey hair, and vaginal infections – Dr. Wolff Group increases sales to over 390 million euros in 2023

Read more
02.01.2024

Successfully combating chalky teeth, grey hair, and vaginal infections – Dr. Wolff Group increases sales to over 390 million euros in 2023

In total, the Bielefeld-based Dr. Wolff Group achieved a preliminary annual revenue of 390.6 million euros in the fiscal year 2023. The company thus exceeded the previous year's sales of 363.8 million euros and continued its long-term growth.

Read more

Innovations accelerate growth of Dr. Wolff Group

Read more
10.08.2023

Innovations accelerate growth of Dr. Wolff Group

In the first half of the year, the Dr. Wolff Group was able to increase sales by 6 percent compared to the same period of the previous year. "We currently expect further growth above average for the remainder of the year, so that we should reach sales of 400 million euros by the end of the year as planned," Managing Partner Eduard R. Dörrenberg predicts.

Read more

Long-term study shows efficacy of hydroxyapatite in cavity prevention

Read more
20.07.2023

Long-term study shows efficacy of hydroxyapatite in cavity prevention

Modern dental care products are demanded to be safe and effective while providing a good feeling in the mouth as well as having a scientifically proven effect. One of the most important tasks of toothpaste and its ingredients includes the prevention of cavities, also known as dental caries. Hydroxyapatite is one such active ingredient that fulfils these criteria. A recently published long-term clinical study shows again that hydroxyapatite is as effective as fluoride in cavity prevention.

Read more

Dr. Wolff presents latest research results on caffeine at international hair congress

Read more
06.07.2023

Dr. Wolff presents latest research results on caffeine at international hair congress

At the 20th European Hair Research Society Meeting in Sheffield, England, Dr. Erik Schulze zur Wiesche, Head of the Medical Scientific Department at Dr. Wolff, presented the latest findings from hair research on the active ingredient combination of caffeine and DMG.

Read more

Dr. Wolff continues to grow and focuses on a new caffeine moment

Read more
07.06.2023

Dr. Wolff continues to grow and focuses on a new caffeine moment

After 2022, which ended as a transitional year with a slight increase and a revenue of 363.8 million euros (357.2 million in 2021), Bielefeld-based Dr. Wolff Group continues its positive trend in the current fiscal year with its pharmaceutical and cosmetic divisions. Revenue has grown by four percent in the first five months compared to the same period last year. Thanks to further innovations, a growth of up to ten percent is expected for the year 2023.

Read more

Dr. Wolff continues to grow and targets 400 million euros turnover with new health products

Read more
03.01.2023

Dr. Wolff continues to grow and targets 400 million euros turnover with new health products

Despite generally difficult global conditions and a noticeable decline in the hygiene and disinfection market, Dr. Wolff Group again increased sales in the past year.

Read more

Dr. Wolff informs with platform “NervtDichDeinSchwitzen.de” about illness hyperhidrosis

Read more
25.11.2022

Dr. Wolff informs with platform “NervtDichDeinSchwitzen.de” about illness hyperhidrosis

Sweating. A vital process, but when people feel they sweat too much, it becomes a burden. Most of all for those who suffer from so-called primary hyperhidrosis – a condition that is characterised by excessively sweating for no apparent reason. To raise awareness of hyperhidrosis among the general public Dr. Wolff launched a digital information platform succinctly named nervtdichdeinschwitzen.de (= does your sweating annoy you)

Read more

Asia-Pacific Conference in Singapore Meets World’s Biggest Shopping Event “Singles Day“

Read more
18.11.2022

Asia-Pacific Conference in Singapore Meets World’s Biggest Shopping Event “Singles Day“

Despite the pandemic and the lockdown, Bielefeld-based family company Dr. Wolff sees great potential in the Asian market and is consistently expanding its commitment there.

Read more

Dr. Wolff Group increases turnover again in 2021 to a new record level – 2022 off to a good start despite global crises

Read more
28.06.2022

Dr. Wolff Group increases turnover again in 2021 to a new record level – 2022 off to a good start despite global crises

The Bielefeld-based Dr. Wolff Group recorded the highest turnover to date in the company’s 117-year history at 357.2 million euros (2020: 341.1 million euros), achieved a plus of almost five percent and increased turnover despite Corona in the past two years.

Read more

First anticholinergic cream against heavy underarm sweating currently approved in 11 European countries

Read more
30.05.2022

First anticholinergic cream against heavy underarm sweating currently approved in 11 European countries

Eleven countries have granted marketing authorisation for the topical cream containing 1% glycopyrronium bromide (brand name Axhidrox). The gradual market launch of the product in the respective countries is in preparation.

Read more

Dr. Wolff Group continues successful course in the areas of hair, skin and dental health

Read more
03.01.2022

Dr. Wolff Group continues successful course in the areas of hair, skin and dental health

With an increase to 355 million euros in preliminary turnover the family-owned company successfully stood up to the second year of the pandemic and has increased sales by around 42 million euros since 2019.

Read more

Still on course and defying the crisis with an enormous effort

Read more
22.04.2021

Still on course and defying the crisis with an enormous effort

In 2020, Bielefeld-based Dr. Wolff Group recorded a turnover of 341.1 million euros (2019: 313.4 million euros), an increase of about nine percent, with exports continuing to account for more than 20 percent.

Read more

Alcina hair division and caring cosmetics ensure stable sales

Read more

Alcina hair division and caring cosmetics ensure stable sales

In 2020, Bielefeld-based Dr. Wolff Group recorded an increase of almost nine percent with sales of 341.1 million euros (2019: 313.4 million). With 40.9 million euros in revenue (2019: 44.1 million) Alcina contributed a 12 per cent share to the group's total revenue in 2020.

Read more

Dr. August Wolff and Cantabria Labs enter into an exclusive commercialization agreement for Southern Europe for hyperhidrosis product

Read more
13.04.2021

Dr. August Wolff and Cantabria Labs enter into an exclusive commercialization agreement for Southern Europe for hyperhidrosis product

Promising German-Spanish partnership between Dr. August Wolff GmbH & Co. KG Arzneimittel and Cantabria Labs officially sealed.

Read more

Dr. August Wolff Submits Application for Marketing Authorization of 1% Glycopyrronium Bromide (GPB) Cream in the EU – Positive Phase 3a Part of Pivotal Study Results for 1% GPB Cream in Patients with Primary Axillary Hyperhidrosis

Read more
22.03.2021

Dr. August Wolff Submits Application for Marketing Authorization of 1% Glycopyrronium Bromide (GPB) Cream in the EU – Positive Phase 3a Part of Pivotal Study Results for 1% GPB Cream in Patients with Primary Axillary Hyperhidrosis

The Bielefeld-based family-owned pharmaceutical developing and manufacturing company Dr. August Wolff GmbH & Co. KG Arzneimittel (“Dr. August Wolff”) announces that the “Marketing Authorisation Application” (MAA) for 1% Glycopyrronium bromide (GPB) cream was submitted on February 26th to the Medical Products Agency (MPA, Sweden) despite the challenges of the COVID-19 pandemic.

Read more